Glucose Metabolism Modification Induced by Radioligand Therapy with [¹⁷⁷Lu]Lu/[⁹⁰Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial

[¹⁸F]F-FDG (FDG) PET is emerging as a relevant diagnostic and prognostic tool in neuroendocrine neoplasms (NENs), as a simultaneous decrease in [⁶⁸Ga]Ga-DOTA peptides and increase in FDG uptake (the “flip-flop” phenomenon) occurs during the natural history of these tumors. The...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Luca Urso, Stefano Panareo, Angelo Castello, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Matteo Caracciolo, Eugenia Tonini, Giorgia Valpiani, Alessandra Boschi, Licia Uccelli, Corrado Cittanti, Mirco Bartolomei
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2022-09-01
Cyfres:	Pharmaceutics
Pynciau:	neuroendocrine neoplasms NEN NET radioligand therapy RLT peptide receptor radionuclide therapy
Mynediad Ar-lein:	https://www.mdpi.com/1999-4923/14/10/2009
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!